[go: up one dir, main page]

BRPI0509135A - composição farmacêutica de liberação controlada e método para produzir a mesma - Google Patents

composição farmacêutica de liberação controlada e método para produzir a mesma

Info

Publication number
BRPI0509135A
BRPI0509135A BRPI0509135-7A BRPI0509135A BRPI0509135A BR PI0509135 A BRPI0509135 A BR PI0509135A BR PI0509135 A BRPI0509135 A BR PI0509135A BR PI0509135 A BRPI0509135 A BR PI0509135A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
controlled release
release pharmaceutical
producing
same
Prior art date
Application number
BRPI0509135-7A
Other languages
English (en)
Inventor
Takashi Yoshitake
Mitsuru Mizuno
Kenji Moroshima
Shigeru Aoki
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BRPI0509135A publication Critical patent/BRPI0509135A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

COMPOSIçãO FARMACêTICA DE LIBERAçãO CONTROLADA E MéTODO PARA PRODUZIRA MESMA. é um objeto da presente invenção, no caso uma composição farmacêutica de liberação controlada, particularmente uma composição farmacêutica de liberação por pulso, contendo uma substância ativa fisiologicamente instável em ácido, para prover uma composição farmacêutica que tem pequena variação em tempo de latência de dissolução e alta confiabilidade de características de dissolução. A presente invenção descreve uma composição farmacêutica de liberação controlada compreendendo: a) um núcleo que contém uma substância ativa fisiologicamente instável em ácido e um desintegrante; b) um revestimento de controle de liberação que reveste o núcleo, e que contém um polímero insolúvel em água, um polímero entérico e uma cera hidrofóbica.
BRPI0509135-7A 2004-03-26 2005-03-23 composição farmacêutica de liberação controlada e método para produzir a mesma BRPI0509135A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004093506 2004-03-26
PCT/JP2005/005217 WO2005092336A1 (ja) 2004-03-26 2005-03-23 溶出制御製剤とその製造方法

Publications (1)

Publication Number Publication Date
BRPI0509135A true BRPI0509135A (pt) 2007-08-28

Family

ID=35055974

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509135-7A BRPI0509135A (pt) 2004-03-26 2005-03-23 composição farmacêutica de liberação controlada e método para produzir a mesma

Country Status (17)

Country Link
US (2) US20080095839A1 (pt)
EP (1) EP1728512A1 (pt)
JP (1) JPWO2005092336A1 (pt)
KR (1) KR100794078B1 (pt)
CN (1) CN1938026A (pt)
AU (1) AU2005225283B2 (pt)
BR (1) BRPI0509135A (pt)
CA (1) CA2557791C (pt)
IL (1) IL177087A (pt)
MX (1) MXPA06010785A (pt)
MY (1) MY139427A (pt)
NO (1) NO20064874L (pt)
NZ (1) NZ549838A (pt)
RU (1) RU2337687C2 (pt)
TW (1) TW200602085A (pt)
WO (1) WO2005092336A1 (pt)
ZA (1) ZA200607603B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
BRPI0509135A (pt) * 2004-03-26 2007-08-28 Eisai R&D Man Co Ltd composição farmacêutica de liberação controlada e método para produzir a mesma
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
NZ555693A (en) 2004-12-27 2010-10-29 Eisai R&D Man Co Ltd Matrix type sustained-release preparation containing donepezil
WO2007037259A1 (ja) * 2005-09-29 2007-04-05 Eisai R & D Management Co., Ltd. 生体内での崩壊性を向上させたパルス製剤
EP1872778A1 (en) * 2006-06-29 2008-01-02 LEK Pharmaceuticals D.D. Stable pharmaceutical composition with rabeprazole sodium
DE102006035549A1 (de) 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
WO2008015530A2 (en) * 2006-08-03 2008-02-07 Aurobindo Pharma Limited Stable solid oral formulation of pantoprazole
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
AU2008286914B2 (en) 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
JP4864024B2 (ja) * 2008-02-15 2012-01-25 エスエス製薬株式会社 時限放出製剤
JP2009191034A (ja) * 2008-02-15 2009-08-27 Ss Pharmaceut Co Ltd 時限放出製剤
JP2009191036A (ja) * 2008-02-15 2009-08-27 Ss Pharmaceut Co Ltd 時限放出製剤
EP2255794A1 (en) * 2009-05-29 2010-12-01 H e x a l Aktiengesellschaft Enteric coating
JP5503192B2 (ja) * 2009-06-03 2014-05-28 大原薬品工業株式会社 生理活性物質含有粒子の製造方法
MX2012001178A (es) * 2009-07-30 2012-03-07 Evonik Roehm Gmbh Composicion que consta de un material polimerico anionico y la sal de un acido monocarboxilico saturado que tiene 6 a 22 atomos de carbono.
US8962020B2 (en) * 2012-07-26 2015-02-24 Glycadia Inc. Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid
JP2014122328A (ja) * 2012-11-22 2014-07-03 Shin Etsu Chem Co Ltd 押出成形機又は射出成形機洗浄用組成物及び押出成形機又は射出成形機の洗浄方法
MX2015013231A (es) 2013-03-15 2016-06-07 Inspirion Delivery Technologies Llc Composiciones que disuaden el abuso y metodos de utilizacion.
CN103976972B (zh) * 2014-05-26 2017-09-12 中国药科大学 酒石酸唑吡坦口服脉冲控释给药系统及其制备方法
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
WO2017012935A1 (en) 2015-07-17 2017-01-26 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
EP3117824A1 (en) 2015-07-17 2017-01-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
CN105796532B (zh) * 2016-03-28 2018-12-21 中国医药集团总公司四川抗菌素工业研究所 一种雷贝拉唑钠缓释胶囊及其制备方法
WO2020106735A1 (en) * 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
KR20210071242A (ko) * 2019-12-06 2021-06-16 진양제약주식회사 제약 조성물
US11730708B2 (en) 2019-12-11 2023-08-22 Evonik Operations Gmbh Dosage form for use in treating or preventing of a disease
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
CN113069428B (zh) * 2021-04-02 2023-02-10 珠海润都制药股份有限公司 一种雷贝拉唑钠肠溶片的制备方法
KR102647279B1 (ko) 2021-04-08 2024-03-18 대한뉴팜(주) 라베프라졸의 우수한 방출 특성을 갖는 라베프라졸 나트륨 및 산화마그네슘을 포함하는 제제 및 이의 제조방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
KR930006431B1 (ko) * 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
EP0807433A4 (en) * 1994-12-27 2005-12-28 Akzo Nobel Nv PREPARING WITH DELAYED RELEASE
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6296876B1 (en) * 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
CN1195500C (zh) * 1998-05-18 2005-04-06 武田药品工业株式会社 可口腔崩解的片剂
JP2000128779A (ja) * 1998-10-20 2000-05-09 Mitsui Chemicals Inc 薬物放出制御型製剤
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
US6183766B1 (en) * 1999-02-12 2001-02-06 The Procter & Gamble Company Skin sanitizing compositions
US6174902B1 (en) * 1999-04-28 2001-01-16 Sepracor Inc. R-rabeprazole compositions and methods
JP2001055322A (ja) * 1999-08-18 2001-02-27 Tanabe Seiyaku Co Ltd パルス放出型製剤
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US7220762B1 (en) * 1999-10-20 2007-05-22 Eisai R&D Management Co., Ltd. Methods for stabilizing benzimidazole compounds
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US20020045184A1 (en) * 2000-10-02 2002-04-18 Chih-Ming Chen Packaging system
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
SI21447A (sl) * 2001-11-21 2004-10-31 Eisai Co. Ltd. Sestavek pripravka, ki vsebuje kislinsko nestabilno fiziološko aktivno spojino in postopek priprave le-tega
AU2002258002A1 (en) * 2002-04-29 2003-11-17 Egis Gyogyszergyar Rt A process for the preparation of tablets from pharmaceutically active substances having unfavourable tabletting properties with a granulating liquid comprising microcrystalline cellulose
US20050214371A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
BRPI0509135A (pt) * 2004-03-26 2007-08-28 Eisai R&D Man Co Ltd composição farmacêutica de liberação controlada e método para produzir a mesma
WO2007037259A1 (ja) * 2005-09-29 2007-04-05 Eisai R & D Management Co., Ltd. 生体内での崩壊性を向上させたパルス製剤

Also Published As

Publication number Publication date
RU2006134052A (ru) 2008-04-10
RU2337687C2 (ru) 2008-11-10
CA2557791C (en) 2011-03-08
KR100794078B1 (ko) 2008-01-10
ZA200607603B (en) 2007-05-30
CA2557791A1 (en) 2005-10-06
AU2005225283A1 (en) 2005-10-06
MXPA06010785A (es) 2007-03-28
EP1728512A1 (en) 2006-12-06
US20120003311A9 (en) 2012-01-05
KR20060134124A (ko) 2006-12-27
MY139427A (en) 2009-09-30
IL177087A0 (en) 2006-12-10
JPWO2005092336A1 (ja) 2008-02-07
WO2005092336A1 (ja) 2005-10-06
NZ549838A (en) 2010-04-30
IL177087A (en) 2011-11-30
NO20064874L (no) 2006-12-19
TW200602085A (en) 2006-01-16
AU2005225283B2 (en) 2008-09-18
US20070110806A1 (en) 2007-05-17
CN1938026A (zh) 2007-03-28
US20080095839A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
BRPI0509135A (pt) composição farmacêutica de liberação controlada e método para produzir a mesma
BRPI0414311A (pt) formas de dosagem de liberação controlada
NO20073731L (no) Fast doseringsform omfattende protonpumpeinhibitor, og suspensjon fremstilt derav
BRPI0507473B8 (pt) cápsula de gelatina mole, uso de epa, processo para a manufatura de uma cápsula de gelatina mole, e, uso de uma gelatina porcina tipo a em uma cápsula de gelatina mole
ATE457719T2 (de) Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel
BR112013030727A2 (pt) dispositivos para inalação de insumos medicinais, válvulas e componentes do mesmo
CL2008000219A1 (es) Composicion farmaceutica de liberacion modificada que comprende a uno o mas ingredientes farmaceuticamente activos, con solubilidad dependiente del ph, un polimero controlador de la liberacion, agentes facilitadores de la gelificacion; procedimiento
BR112014029330A2 (pt) métodos, sistemas e dispositivos para administração de fármacos e oclusão vascular
BR112012025406A2 (pt) método de preparação de uma cápsula dura de uso entérico, e cápsula dura de uso entérico.
BRPI0409715A (pt) pelìculas comestìveis de dissolução rápida contendo um edulcorante
BRPI0912842A8 (pt) composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
Han et al. 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD) induces hepatic stellate cell (HSC) activation and liver fibrosis in C57BL6 mouse via activating Akt and NF-κB signaling pathways
CL2008003699A1 (es) Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas.
BRPI0412697A (pt) composições farmacêuticas que apresentam um revestimento expansìvel
Utari et al. The intrasulcular application effect of bisphosphonate hydrogel toward osteoclast activity and relapse movement
Menger et al. Diclofenac, a NSAID, delays fracture healing in aged mice
UY32304A (es) Composición de liberación pulsátil de sildenafil y proceso para prepararla
Cheung et al. Stability and morbidity of Le Fort I osteotomy with bioresorbable fixation: a randomized controlled trial
Demcoe et al. Complications when using threaded K-wire fixation for displaced intra-articular calcaneal fractures
Seo et al. Protein kinase G increases AMPA receptor GluR1 phosphorylation at serine 845 after repeated cocaine administration in the rat nucleus accumbens
BR112018074840A2 (pt) modelos cirúrgicos com marcações radiopacas
BRPI0307319B8 (pt) forma de dosagem oral para liberação controlada de droga e processo para sua preparação
Yassin et al. Design and evaluation of fast dissolving oro-dispersible films of metoclopramide hydrochloride using 32 multifactorial designs
Li et al. Use of 3D-printing cerebral aneurysm model assisting microcatheter shaping in neurovascular intervention technique training
BRPI0514258A (pt) composições e sistemas para uso na cavidade bucal

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.